{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:36Z","timestamp":1791347316883,"version":"4.3.1"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J INFECT DIS"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1086\/518655","type":"journal-article","created":{"date-parts":[[2007,7,25]],"date-time":"2007-07-25T14:13:13Z","timestamp":1185372793000},"page":"S63-S75","source":"Crossref","is-referenced-by-count":168,"title":["Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory Syndrome"],"prefix":"10.1093","volume":"196","author":[{"given":"Helen","family":"McIlleron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William\u00a0J.","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"rf1_465","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.9.1009"},{"key":"rf2_466","unstructured":"World Health Organization (WHO). Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. Geneva: WHO, 2004."},{"key":"rf3_467","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00126334-200001010-00010","volume":"23","author":"Wood R","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"rf4_468","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08904-3"},{"key":"rf5_469","doi-asserted-by":"publisher","DOI":"10.1086\/338641"},{"key":"rf6_470","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009080-00015"},{"key":"rf7_471","first-page":"1026","volume":"4","author":"Jones JL","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"rf8_472","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1164\/ajrccm.162.3.9908018","volume":"162","author":"Kirk O","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"rf9_473","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/01.aids.0000176211.08581.5a","volume":"19","author":"Lawn SD","year":"2005","journal-title":"AIDS"},{"key":"rf10_474","unstructured":"Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Available at: http:\/\/www.cdc.gov\/tb\/TB_HIV_Drugs\/default.htm. Accessed 5 June 2007."},{"key":"rf11_475","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3966-3969.2005"},{"key":"rf12_476","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00003"},{"key":"rf13_477","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"rf14_478","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342060-00009"},{"key":"rf15_479","unstructured":"Hoetelmans RMW, Van Heeswijk RPG, Meenhorst PL. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period [abstract 42261]. In: Program and abstracts of the 12th World AIDS Conference (Geneva). Geneva: International AIDS Society, 1998."},{"key":"rf16_480","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200008000-00007"},{"key":"rf17_481","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.2926-2932.2002"},{"key":"rf18_482","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201040-00010"},{"key":"rf19_483","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702004000300004"},{"key":"rf20_484","unstructured":"Rolla V, Vieira A, Pereira-Pinto D, etal Safety, efficacy and pharmacokinetics of ritonavir 400mg-saquinavir 400mg and rifampicin combined therapy in HIV patients with tuberculosis [abstract WePe3.3C03]. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). Geneva: International AIDS Society, 2005."},{"key":"rf21_485","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70140-7"},{"key":"rf22_486","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200503-417OC"},{"key":"rf23_487","doi-asserted-by":"publisher","DOI":"10.1086\/430377"},{"key":"rf24_488","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11467-8"},{"key":"rf25_489","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4473-4475.2004"},{"key":"rf26_490","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1170-1177.2006"},{"key":"rf27_491","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-127-4-199708150-00006","volume":"127","author":"Sahai J","year":"1997","journal-title":"Ann Intern Med"},{"key":"rf28_492","first-page":"1360","volume":"8","author":"Zhu M","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"rf29_493","doi-asserted-by":"publisher","DOI":"10.1086\/429321"},{"key":"rf30_494","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-951OC"},{"key":"rf31_495","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","volume":"299","author":"Rae JM","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"rf32_496","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"rf33_497","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90134-X"},{"key":"rf34_498","unstructured":"Benedek IH, Joshi A, Fiske WD, etal Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [abstract 42280]. In: Program and abstracts of the 12th World AIDS Conference (Geneva). Geneva: International AIDS Society, 1998."},{"key":"rf35_499","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241090-00004"},{"key":"rf36_500","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.979-984.2004"},{"key":"rf37_501","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183519.45137.a6"},{"key":"rf38_502","unstructured":"Almond L, Gibbons S, Davies G, Back D, Khoo S. A retrospective survey of the Liverpool TDM Service: factors influencing efavirenz concentrations in patients taking rifampicin [abstract 19]. In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy (Quebec). Utrecht: Virology Education, 2005:15."},{"key":"rf39_503","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.130-137.2003"},{"key":"rf40_504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/135965350501000114","volume":"10","author":"Kappelhoff BS","year":"2005","journal-title":"Antivir Ther"},{"key":"rf41_505","first-page":"2391","volume":"18","author":"Haas DW","year":"2004","journal-title":"AIDS"},{"key":"rf42_506","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.05.116"},{"key":"rf43_507","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183630.27665.30"},{"key":"rf44_508","unstructured":"Jack C, Khoo S, Lalloo U, Naidoo V, Friedland G. Efavirenz levels and clinical outcomes in patients with TB and HIV treated concomitantly with ART and rifampin containing TB regimen [abstract 891]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005."},{"key":"rf45_509","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000135956.96166.f0"},{"key":"rf46_510","unstructured":"Cohen K, Van Cutsem G, Saranchuk P, etal ART treatment outcomes for TB\/HIV co-infected patients [abstract WePp0303]. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). Geneva: International AIDS Society, 2005."},{"key":"rf47_511","unstructured":"Autar RS, Wit F, Sankote J, etal Nevirapine plasma concentrations in the presence of rifampicin (HIV-NAT 025) [abstract 21]. In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy (Quebec). Utrecht: Virology Education, 2005:16."},{"key":"rf48_512","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","volume":"28","author":"Ribera E","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"rf49_513","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00002"},{"key":"rf50_514","unstructured":"Cohen K, Van Cutsem G, Boulle A, etal The nucleoside reverse transcriptase inhibitors and rifampicin. In: Program and abstracts of the 39th Congress of the South African Pharmacology Society (Cape Town). Potchefstroom: South African Pharmacology Society, 2005:22."},{"key":"rf51_515","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200303070-00024"},{"key":"rf52_516","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000188990.57760.e3"},{"key":"rf53_517","doi-asserted-by":"publisher","DOI":"10.1086\/428093"},{"key":"rf54_518","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00018"},{"key":"rf55_519","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00126334-200003010-00004","volume":"23","author":"Bonfanti P","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"rf56_520","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1553-1560.2004"},{"key":"rf57_521","unstructured":"Burger D, Agarwala S, Child M, Wang Y, Grasela D. Effect of rifampin on steady-state pharmacokinetics of atazanavir and ritonavir in healthy subjects [abstract 657]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005."},{"key":"rf58_522","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/135965350400900606","volume":"9","author":"Losso MH","year":"2004","journal-title":"Antivir Ther"},{"key":"rf59_523","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000182629.74336.4d"},{"key":"rf60_524","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1128\/AAC.37.7.1426","volume":"37","author":"Burger DM","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"rf61_525","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003259220"},{"key":"rf62_526","doi-asserted-by":"publisher","DOI":"10.1080\/00498250500136569"},{"key":"rf63_527","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.045096"},{"key":"rf64_528","unstructured":"Muirhead G, Russell D, Pozniak A, etal A novel probe drug interaction study to investigate the effect of selected ARV combinations on the PK of a single oral dose of Maraviroc in HIV +ve subjects [abstract 31]. In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy (Quebec). Utrecht: Virology Education, 2005:21."},{"key":"rf65_529","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1164\/ajrccm\/136.3.570","volume":"136","author":"Chaisson RE","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"rf66_530","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC"},{"key":"rf67_531","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503233321204"},{"key":"rf68_532","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000152400.36723.85"},{"key":"rf69_533","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00002030-198812000-00003","volume":"2","author":"Soriano E","year":"1988","journal-title":"AIDS"},{"key":"rf70_534","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200408010-00006"},{"key":"rf71_535","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.05.010"},{"key":"rf72_536","unstructured":"Grange S, Schutz M, Schmitt C, Riek M, Gaudeul-Ehrhart E. Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted saquinavir and vice versa [abstract 35]. In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy (Quebec). Utrecht: Virology Education, 2005:27."},{"key":"rf73_537","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131375.21070.06"},{"key":"rf74_538","doi-asserted-by":"publisher","DOI":"10.1086\/383034"},{"key":"rf75_539","doi-asserted-by":"publisher","DOI":"10.1086\/425742"},{"key":"rf76_540","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/517636","volume":"26","author":"Crump JA","year":"1998","journal-title":"Clin Infect Dis"},{"key":"rf77_541","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6339-1"},{"key":"rf78_542","doi-asserted-by":"publisher","DOI":"10.1086\/381441"},{"key":"rf79_543","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0821-2"},{"key":"rf80_544","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2214\/ajr.174.1.1740043","volume":"174","author":"Fishman JE","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"rf81_545","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/ajrccm.158.1.9712001","volume":"158","author":"Narita M","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"rf82_546","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.1.97"},{"key":"rf83_547","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.1.193"},{"key":"rf84_548","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.019224"},{"key":"rf85_549","first-page":"201","author":"Burman W","year":"2004","journal-title":"VA: Infectious Diseases Society of America"},{"key":"rf86_550","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200412150-00007"},{"key":"rf87_551","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/135965350501000303","volume":"10","author":"Michailidis C","year":"2005","journal-title":"Antivir Ther"},{"key":"rf88_552","first-page":"71","volume":"6","author":"Olalla J","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"rf89_553","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000161769.06158.8a"},{"key":"rf90_554","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5694\/j.1326-5377.1998.tb123372.x","volume":"169","author":"John M","year":"1998","journal-title":"Med J Aust"},{"key":"rf91_555","unstructured":"Baalwa J, Mayanja-Kizza H, Kamya M, Laurence J, Colebunders R. Mycobacterium tuberculosis immune reconstitution inflammatory syndrome in Uganda. In: Program and abstracts of the 36th International Union Against Tuberculosis and Lung Disease World Conference on Lung Health (Paris). Paris: International Union Against Tuberculosis and Lung Disease, 2005."},{"key":"rf92_556","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.aids.0000176221.33237.67","volume":"19","author":"Breen RA","year":"2005","journal-title":"AIDS"},{"key":"rf93_557","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90519-7"},{"key":"rf94_558","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/ajrccm.159.3.9804147","volume":"159","author":"Murray J","year":"1999","journal-title":"Am J Resp Crit Care Med"},{"key":"rf95_559","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031772"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/196\/Supplement_1\/S63\/2412460\/196-Supplement_1-S63.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T22:13:45Z","timestamp":1737324825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1086\/518655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":95,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1086\/518655"],"URL":"https:\/\/doi.org\/10.1086\/518655","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}